This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban , Journal of Pharmacology and Experimental Therapeutics, May 2022, American Society for Pharmacology & Experimental Therapeutics (ASPET),
DOI: 10.1124/jpet.122.001222.
You can read the full text:
The following have contributed to this page
